Name | PF-06821497 |
---|
Description | PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition[1]. |
---|---|
Related Catalog | |
Target |
Ki: <0.1 nM (Y641N EZH2)[1]. |
In Vivo | PF-06821497 (compound 23a: 100 mg/kg, PO twice daily for 31 days) treatment results in significant inhibition of tumor growth, and the the tumor regressition effect can be sustained for another 40 days after the terminal administration[1]. PF-06821497 with the dose of 300 mg/kg has minimal impact on animal body weights[1]. Animal Model: Mice bearing Karpas-422 DLBCL tumor xenografts (which contain the Y641N EZH2 mutation)[1]. Dosage: 100 mg/kg and 300 mg/kg. Administration: PO twice daily for 31 days. Result: 100 mg/kg dose resulted in significant inhibition of tumor growth and 300 mg/kg dose minimal effected animal body weights. |
References |
Molecular Formula | C22H24Cl2N2O5 |
---|---|
Molecular Weight | 467.34 |